Emerging Dutch biotech, NorthSea Therapeutics (NST), has raised €25m to move its NASH drug icosabutate into Phase IIb next year; with dual modality that targets both metabolic and anti-inflammatory aspects of this form of liver disease, NorthSea believes its drug can stand out from the numerous pipeline competitors.
NorthSea Raises Cash For NASH Program
NorthSea raises €25m to push icosabutate, its only clinical compound, which was licensed from Pronova BioPharma, into Phase IIb trials for fatty liver disease. The drug has previously been tested in hypertriglyceridemia and dyslipidemia.
More from Strategy
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
More from Business
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.